Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : BARDA
Deal Size : $0.7 million
Deal Type : Funding
BARDA Partners with Tiba Biotech to Develop Innovative Therapeutics Against Influenza
Details : Tiba Biotech's initial focus will be on developing a prototype RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein & will be delivered via Tiba's platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : BARDA
Deal Size : $0.7 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?